Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2020 at "Kidney international"
DOI: 10.1016/j.kint.2020.04.051
Abstract: Canagliflozin reduced kidney disease progression in participants with type 2 diabetes in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program that explored potential mediators of the effects of canagliflozin on kidney outcomes. The percent mediating effect… read more here.
Keywords: effects canagliflozin; effect; canagliflozin kidney; type diabetes ... See more keywords
EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)32479-7
Abstract: Canagliflozin (CANA) reduces the risk of cardiovascular (CV) events and kidney failure in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Inherent in its mechanism of action is enhanced natriuresis and… read more here.
Keywords: canagliflozin cardiovascular; safety outcomes; renal safety; safety ... See more keywords
Abstract P2044: Renoprotective Effects of Canagliflozin in Db/db Diabetic Mice
Sign Up to like & getrecommendations! Published in 2019 at "Hypertension"
DOI: 10.1161/hyp.74.suppl_1.p2044
Abstract: Diabetes is one of the major causes of chronic kidney disease which could lead to end-stage renal disease. Previously, we have shown increased urinary angiotensin converting enzyme 2 (ACE2) and neprilysin (NEP) in db/db mouse… read more here.
Keywords: effects canagliflozin; renoprotective effects; expression; mice ... See more keywords